Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? an application to derive a Lopinavir-Score

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Cozzi Lepri, Alessandro ^a,b   Prosperi, Mattia C F ^c   Kjær, Jesper ^d   Dunn, David ^e   Paredes, Roger ^f   Sabin, Caroline A ^a   Lundgren, Jens D ^d,g   Phillips, Andrew N ^a   Pillay, Deenan ^h  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g Mental Health Center Glostrup   (Denmark)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; EXPERT SYSTEM; GENETIC DATABASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; PERFORMANCE MEASUREMENT SYSTEM; SCORING SYSTEM; STATISTICAL MODEL; VALIDATION PROCESS; VIRUS MUTATION; WEB BROWSER; DRUG EFFECT; GENETICS; HEALTH CARE PERSONNEL; HUMAN IMMUNODEFICIENCY VIRUS; INTERNET; MUTATION; STATISTICAL ANALYSIS;

COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEALTH PERSONNEL; HIV; HIV INFECTIONS; HUMANS; INTERNET; LINEAR MODELS; LOPINAVIR; MUTATION;

EID: 81255179310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025665     Document Type: Article

References (39)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352: 1725-1730.
2. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853-860.
3. Vella S, (1995) HIV pathogenesis and treatment strategies. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10: S20-S23.
4. Grant RM, Feinberg MB, (1996) HIV replication and pathogenesis. Current Opinion in Infectious Diseases 9 (1): 7-13.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents (2009) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1-139 Department of Health and Human Services.
6. BHIVA Guidelines for the Treatment of HIV-1 infected adults with antiretroviral therapy (2008) Available: http://www.bhiva.org/files/file1030835.pdf Accessed 2011 August.
7. World Health Organization (WHO) (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public heath approach. Geneva, Switzerland. Available: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 2009 April 2.
8. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, et al. (2001) Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 75: 7462-7469.
9. Parkin N, Chappey C, Petropoulos C, (2003) Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17: 955-961.
10. Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, et al. (2004) Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 9 (4): 595-602.
11. King MS, Rode R, Cohen-Codar I, Calvez V, Marcelin AG, et al. (2007) Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother 51 (9): 3067-74.
12. Abbott Pharmaceuticals (2004) Lopinavir/ritonavir (Kaletra) US Prescribing Information. Abbott Laboratories. Available: http://rxabbott.com/pdf/kaletratabpi.pdf Accessed 2008 May 19.
13. Naeger L, Struble K, (2006) Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 20: 847-853.
14. Grant P, Wong EC, Rode R, Shafer R, De Luca A, et al. (2008) Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Antimicrob Agents Chemother 52 (11): 4050-6.
15. Hill A, Marcelin AG, Calvez V, (2009) Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. HIV Med 10 (10): 620-6.
16. Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, et al. (2010) Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med 12 (4): 211-8.
17. Prosperi MC, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, et al. (2009) EuResist and Virolab study groups. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther 14 (3): 433-42.
18. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, et al. (2008) Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis 15;198 (4): 470-80.
19. Assoumou L, Houssaïni A, Costagliola D, Flandre P, (2010) Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. J Antimicrob Chemother 65 (4): 752-60.
20. Larder B, Wang D, Revell A, (2008) Application of artificial neural networks for decision support in medicine. Methods Mol Biol 458: 123-36.
21. Kirk O, EuroSIDA a multicentre study, 1994-2009. Available: http://www.cphiv.dk/EuroSIDA/Publications/EuroSIDAamulticentrestudy19942 009/tabid/407/Default.aspx. Accessed 2011 August.
22. UK Collaborative HIV Cohort (UK CHIC) Steering Committee (2004) The creation of a large UK-based multicantre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine 5: 115-124.
23. ANRS website. Available: http://www.hivfrenchresistance.org/2010/Algo-2010.pdf Accessed 2011 August.
24. Rega Institute website. Available: http://www.rega.kuleuven.be/cev/index.php?id=30. Accessed 2011 August.
25. Stanford University website. Available: http://hivdb.stanford.edu/pages/asi/releaseNotes/updates.html#Ver6.0.9_2 0100824 Accessed 2011 August.
26. IAS-USA HIV resistance list website. Available: http://www.iasusa.org/resistance_mutations/mutations_figures.pdf Accessed 2011 August.
27. Tibshirani R, (1996) Regression shrinkage and selection via the lasso. J Royal Statist Soc B 58 (1): 267-288.
28. Efron B, Hastie T, Johnstone I, Tibshirani R, (2004) Least angle regression. Ann Statist 32 (2): 407-499.
29. Altmann A, Beerenwinkel N, Sing T, Savenkov I, Doumer M, et al. (2007) Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther 12 (2): 169-78.
30. González de Requena D, Gallego O, Valer L, Jiménez-Nácher I, Soriano V, (2004) Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 20 (3): 275-8.
31. Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, et al. (2007) The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J Clin Virol 38 (2): 131-8 Epub 2007 Jan 4.
32. Gianotti N, Galli L, Danise A, Hasson H, Boeri E, et al. (2006) Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. J Med Virol 78 (12): 1537-41.
33. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, et al. (2010) Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS 24 (3): 365-71.
34. Prosperi MC, Rosen-Zvi M, Altmann A, Zazzi M, Di Giambenedetto S, et al. (2010) EuResist study group; Virolab study group. Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS One 5 (10): e13753.
35. Rosen-Zvi M, Altmann A, Prosperi M, Aharoni E, Neuvirth H, et al. (2008) Selecting anti-HIV therapies based on a variety of genomic and clinical factorss. Bioinformatics 1;24 (13): i399-406.
36. Buendia P, Cadwallader B, DeGruttola V, (2009) A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics 25 (19): 2522-9.
37. Beerenwinkel N, Drton M, (2007) A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. Biostatistics 8 (1): 53-71.
38. Bogojeska J, Bickel S, Altmann A, Lengauer T, (2010) Dealing with sparse data in predicting outcomes of HIV combination therapies. Bioinformatics 1;26 (17): 2085-92.
39. Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, et al. (2008) EuroSIDA Study Group. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther 13 (3): 399-407.